Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 10Lung Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Neoplasms 5Head and Neck Neoplasms 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Squamous Cell 5Neoplasm Metastasis 4Colorectal Neoplasms 4Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma 3Esophageal Neoplasms 3Urinary Bladder Neoplasms 2Non-small-cell Lung Cancer With Somatic EGFR Mutations 2Hematologic Neoplasms 2Glioma 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Unilateral HER2 Positive Breast Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Cancers of the Head and Neck 1Solid Tumors 1

Interventions

Bevacizumab 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × PFS × Afatinib × Clear all
NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Qingdao Central Hospital

Phase 2 Unknown
30 enrolled

PFS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡